NCT01687387

Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)

Double-Blind Placebo-Controlled Randomized Phase 2 Study of IPH2102 as Maintenance Treatment in Elderly Patients With Acute Myeloid Leukemia (AML) in First Complete Remission

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 152 (actual)
• Sponsor: Innate Pharma · Industry
• Sex: All
• Age: 60 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Double-Blind Placebo-Controlled Randomized Phase 2 Study evaluating the efficacy of lirilumab (IPH2102/BMS-986015) as Maintenance Treatment administered in elderly patients with Acute Myeloid Leukemia (AML) in first complete remission

Conditions

• Acute Myeloid Leukemia

Interventions

Type	Name	Description
DRUG	IPH2102 at 0.1 mg/kg	every 3 months
DRUG	IPH2102 at 1 mg/kg	every 4 weeks
DRUG	Placebo (normal saline solution)	every 4 weeks

Timeline

• Start date: 2012-10-01
• Primary completion: 2016-11-17
• Completion: 2016-11-17
• First posted: 2012-09-18
• Last updated: 2019-02-08
• Results posted: 2019-02-08

Locations

43 sites across 1 country: France